- Received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within 3 weeks (4 weeks for monoclonal antibodies or investigational drugs, 1 week for tyrosine kinase inhibitor (TKI) (e.g. erlotinib, gefitinib) or the patient has not recovered (from grade ≥2 side effects of the previous therapy) prior to lymphodepletion regimen.